A year after taking targeted drugs for lung cancer, my sternum hurts a little
A year after a lung cancer patient took the targeted drug, there could be a variety of reasons for the pain in the sternum. On the one hand, this may be a side effect of the targeted drug. For example, gefitini may cause chest pain, which is usually mild and may gradually reduce as the drug continues to be used. On the other hand, lung cancer itself could also cause chest pain, especially when the disease progressed to the late stage. In addition, if the patient also had heart disease, such as heartache, similar symptoms might appear. Therefore, it was recommended that patients who experienced stabbing pain in their sternum should seek medical attention in time for a detailed examination. The doctor would conduct a comprehensive analysis based on the patient's specific condition, combined with factors such as drug use history and disease history to determine the specific cause of the stinging pain. Read more exciting novels for free
Is it always effective to take targeted drugs for lung cancer?
The effect of targeted drugs on lung cancer patients was not very good. Target drugs could not cure lung cancer. Although they could prolong survival time, they could not always be effective. There were very few driver mutations in lung cancer, so there were relatively few targeted drugs that could be used. When using targeted drugs, it was necessary to find the target of lung cancer and could not be used blindly. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long will it take for targeted drugs to be effective for lung cancer?
Patients with lung cancer usually took targeted drugs for ten days, no more than forty days, and the effect would take effect in two to three days. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
70-year-old advanced lung cancer can live for a few years with targeted drugs
For patients with late-stage lung cancer who took targeted drugs, the time from the start of treatment to the progression of the disease or the patient's death was 9.2 to 18.9 months. The general overall survival period was 21.6 to 36 months. There was also data that showed that the average survival time was about three years, but this was only a rough range. The specific situation needs to be determined based on the patient's physical condition (such as whether the patient has cardiovascular diseases, chronic rheumatism, liver diseases, and other basic diseases), the effect of targeted therapy, the patient's attitude and degree of cooperation with the treatment, as well as the support, care, and economic investment of the family members. There are individual differences. Some studies had shown that after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the mean survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the mean survival time was 6 months. In addition, with the deepening of targeted drug research, more efficient targeted drugs could effectively prolong the survival of patients with advanced lung cancer. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What is the survival rate of targeted drugs in the treatment of advanced lung cancer?
There was a large individual difference in the survival rate of patients with advanced lung cancer after taking targeted drugs. The time from the start of treatment to disease progression or death was 9.2 - 18.9 months, and the general overall survival period was 21.6 - 36 months. Some studies had shown that the average survival time for late-stage lung cancer patients with targeted drugs was about three years, but there were also cases where it was as short as one or two years and as long as ten years. According to the data, after comprehensive treatment, the 2-year survival rate of stage IUA lung cancer patients was 23%, the 5-year survival rate was 10%, and the medium survival time was 11.5 months. For stage IUA lung cancer patients who had multiple metastasies, the 2-year survival rate was 10%, and the medium survival time was 6 months. In addition, in some studies, the 1-year, 2-year, 3-year, 4-year, and 5-year overall survival rates of the control group (first-line therapy with a combination of a combination The patient's physical condition, the effect of the targeted therapy, whether the attitude was positive, the degree of cooperation with the treatment, whether the patient had underlying diseases, and the support, care, and financial investment of the family would all affect the survival rate. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
How long do you take targeted drugs for lung cancer?
The time taken for targeted treatment of lung cancer needed to be considered from both the patient's own condition and the progression of the disease. For patients with middle-stage lung cancer, it is recommended to take the first-generation targeted drug for 1.5 - 2 years or the third-generation targeted drug for 3 years. For patients with advanced lung cancer, as long as the targeted drug was effective, it was recommended to take it until the disease progressed. If drug resistance appeared, the targeted drug would need to be replaced. However, it should be noted that the premise of using targeted drugs was that the patient must have a clear target for treatment in the body, and there must be a specific drug targeting the target before targeted drug therapy could be carried out. Less than 20% of lung cancer patients could find targeted drugs. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Does lung cancer have targeted drugs that need to be taken all the time?
Whether or not targeted drugs for lung cancer needed to be taken all the time could not be said to be the same. On the one hand, targeted drugs may face the problem of drug resistance in cancer cells during treatment. Due to the rapid evolution of cancer cells, new genetic mutations may occur during the targeted drug treatment to avoid the targeted drug attack, resulting in drug resistance in the body. Once this happens, the targeted drug may not be able to continue to effectively suppress tumor growth. At this time, it may be necessary to change the treatment plan, such as switching to other targeted drugs or changing to chemotherapy. On the other hand, if the patient had a good response to the targeted drug and did not have any serious adverse reactions or drug resistance, from the perspective of continuous suppression of tumor cell growth and prevention of cancer relapse and migration, it might be necessary to continue taking the targeted drug to maintain the treatment effect. At the same time, factors such as the patient's actual disease progression and overall physical condition would also affect the duration of the targeted drug's use. The specifics should be determined according to the diagnosis of a professional doctor. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
What are the effects of taking targeted drugs in the late stage of liver cancer?
There may be the following symptoms when taking targeted drugs for late-stage liver cancer: - If the condition was under control and the tumor growth was suppressed, the tumor might shrink. - For patients with late-stage liver cancer who developed ascitic fluid, if their stomachs gradually subsided after taking the targeted drug, it might mean that the ascitic fluid decreased and the condition was controlled to a certain extent. - The patient's condition was stable. For example, although the tumor did not shrink after taking the targeted drug, its growth rate slowed down. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Late stage liver cancer, taking targeted drugs, black stool discharge
There may be many reasons for black stool discharge in patients with late-stage liver cancer when taking targeted drugs. The following is the specific analysis and countermeasures: ##1. Reason Analysis 1. ** Drug factor ** - The targeted drug may cause bleeding in the digestive tract. The hemoglobinin the blood will turn black after digestion in the intestine, resulting in black feces. 2. ** Disease-related factors ** - Patients with late-stage liver cancer may have coagulated due to tumor invasion of the liver, which may lead to digestive tract bleeding. In addition, bleeding from the ruptured esophagus and gastric varices caused by portal vein hypertention was also a common cause. 3. ** Dietary factors ** - Although it is rare, eating too much black food recently (such as mulberries, animal blood products, etc.) may also cause the color of the stool to turn black. ##2. Treatment 1. ** See a doctor immediately ** - After black stool appears, the patient should immediately seek medical attention and describe the symptoms and medication to the doctor in detail. 2. ** Complete relevant checks ** - The doctor may arrange for a stool occult blood test, a colonoscopy, and other examinations to determine if there is any bleeding in the digestive tract and its cause. 3. ** Adjusts treatment plan ** - According to the results of the examination, the doctor may adjust the dose of the targeted drug or change the drug to reduce the risk of digestive tract bleeding. 4. ** Bleeding control treatment ** - If a diagnosis of digestive tract bleeding was confirmed, the doctor might give hemostatic drugs (such as vitamins K1, tranexamic acid, etc.) to promote the synthesis of blood clot factors and reduce bleeding. 5. ** Protect gastric mucus ** - The damaged liver function of patients with late-stage liver cancer may affect the secretion and secretion of bile, causing bile to flow back into the stomach and cause damage to the gastric mucus. At this time, you can use a protective agent for the digestive tract (such as aluminum magnesite, sucralfate, etc.) to neutralize gastric acid and protect the gastric mucus. 6. ** Nutritional support ** - Patients with late-stage liver cancer were usually in poor physical condition, and nutritional supplements (such as compound aa, fat milk, etc.) could provide the necessary nutrients to support the patient's recovery process. 7. ** Pay attention to rest ** - The patient should pay attention to rest and avoid overwork to avoid increasing the burden on the liver. In short, the blackness of patients with late-stage liver cancer during targeted drug therapy was a symptom that needed to be taken seriously. Patients should pay close attention to the changes in their symptoms. If they have persistent black stool or other discomfort symptoms, they should inform the doctor in time. At the same time, they should maintain good eating habits, avoid eating food that may increase the burden on the stomach and intestines, and follow the doctor's advice for treatment and adjustment. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
Is there reimbursement for Changde lung cancer targeted drug?
Based on the information provided so far, it was impossible to determine whether Changde's targeted lung cancer drug was eligible for reimbursement. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>
There are several types of breast cancer targeted drugs
There were mainly the following types of breast cancer targeted drugs: 1. Anti-neoplastic targeted drugs: There are intravenous preparations and oral drugs, but the effect in the treatment of breast cancer is not ideal. For example, bevacidol (Avastin) will be considered in some cases. 2. Anti-Her- 2 targeted drugs: targeted at HER - 2 positive patients, it is the most important targeted drug for breast cancer, mainly including trastuzumab (Herceptin), pertubizab, dm- 1, lapatini, etc. The prerequisite for use was that the patient was positive for HER - 2 (+++ in the immune tissue test). If the immune tissue test was ++, the patient would need to undergo a further FISH test. The patient could only be used if the FISH test was positive. If the immune tissue test was + or-, the patient could not be used. 3. A targeted drug for patients with fetal mutations in the Brca lineage: The main drug is olaparib, which is used to treat patients with metastasizing breast cancer who have harmful or suspected harmful mutations in the Brca lineage and who are negative for the human embryonic growth factor receptor 2 (HEL2). 4. Immune therapy (in a sense, it was also a targeted drug): Anti-PD- 1/PD-L1 Monoclone Antibodies, which essentially relieved immune suppression and activated immune cells to kill cancer cells. 5. mTO inhibition drugs, such as everolimus and sirolimus, can inhibit the activation of the mTO signaling pathway, thereby suppressing the growth and metabolism of tumor cells. 6. Other targeted therapy drugs, such as Parp inhibition drugs, CD 4/6 inhibition drugs, etc. <a href="/?from=ask_words" style="color:red" target="_blank">Read more exciting novels for free</a>